Vasculitis & polymyalgia rheumatica
Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid‐Dependent Polymyalgia Rheumatica
Authors' conclusion
Among patients with GC-dependent PMR in remission after a six-month TCZ treatment, only a minority of the patients remained relapse-free after TCZ discontinuation.
Study context
- Population
- Patients with glucocorticoid (GC)-dependent polymyalgia rheumatica (PMR) who achieved remission (PMR-AS <10 and GC dose reduction) at week 24 of tocilizumab (TCZ) in the SEMAPHORE trial26 followed to week 48
- Participants
- 33 patients
- Primary endpoint
- Relapse after stopping TCZ (failure of the primary composite outcome during follow-up or need for ≥1 TCZ infusion)
- Follow-up
- Week 48
Methodological detailssingle-group follow-up after TCZ withdrawal, Kaplan-Meier analysis
- Single-group follow-up after TCZ withdrawal
- Kaplan-Meier analysis
Primary result
As reported in the abstract
Relapse after TCZ withdrawal (failure of primary composite outcome or need for ≥1 TCZ infusion)
Patients who experienced a relapse
24
92.3%
Patients with sustained remission in the following six months
2 of 26
7.7%
Further findings
- Median time to relapse
- 15 weeks (IQR, 8-25 weeks)
- Kaplan-Meier analysis
Original publication
Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid‐Dependent Polymyalgia Rheumatica. Arthritis Rheumatol. Published 29 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →